Loading patent…
AssigneesAarhus Universitet, Region Midtjylland
InventorsSøren Gregersen, Per Bendix Jeppesen, Kjeld Hermansen, Fredrik Brustad Mellbye
Estimating the term…
A method is provided of treating, preventing or ameliorating type 2 diabetes and/or a clinical condition associated with type 2 diabetes, which method comprises administering an effective amount of cafestol or a derivative thereof including esters and salts thereof to a person in need thereof. Further provided are compositions comprising cafestol and at least one additional agent suitable for treating, preventing or ameliorating diabetes and/or a clinical condition associated with diabetes. A method is also provided of increasing insulin secretion and/or increasing insulin-dependent glucose uptake, said method comprising administering an effective amount of cafestol or a derivative thereof to a person in need thereof.
A method of treating, preventing or ameliorating insulin resistance, which method comprises administering a pharmaceutical formulation comprising isolated and purified cafestol, kahweol or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof, wherein said isolated and purified cafestol, kahweol or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof is at least 70% pure, and wherein said isolated and purified cafestol, kahweol or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof is administered in a dosage of 30-500 mg daily to a person in need thereof.
A method of increasing insulin secretion and/or increasing insulin dependent glucose uptake, said method comprising administering an effective amount of isolated and purified cafestol, kahweol or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof to a person in need thereof, wherein said isolated and purified cafestol, kahweol or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof is at least 70% pure, and wherein said isolated and purified cafestol, kahweol or pharmaceutically acceptable salts, solvates, esters or prodrugs thereof is administered in a dosage of 30-500 mg daily.
Dependencies are inferred from the claim text.